Alydia Health, a commercial-stage medical device company, has been bought by women’s healthcare company Organon. The former’s main focus is the prevention of maternal morbidity and mortality caused by postpartum haemorrhage, one of the most common complications of birth, or abnormal postpartum uterine bleeding. In 2016 40,510 women across the world women died due to PPH. Organon’s focus is on women’s reproductive health, health issues that affect women and conditions that disproportionately affect women.
Organon CCO, Susanne Fiedler, said: “With our global commercial footprint in reproductive health and experience creating affordable access in the world’s least developed markets, we will look for ways to bring the Jada System to more women around the world.”
“This acquisition brings us one step closer to our vision of a better and healthier every day for every woman around the world.“
Organon CEO, Kevin Ali, said: “Organon’s acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’s unmet medical needs. This acquisition brings us one step closer to our vision of a better and healthier every day for every woman around the world.”
Alydia Health CEO, Rob Binney, said: “Alydia Health is thrilled to be joining a company that can help progress our founding vision through its commitment to listen to women, to understand her health needs and to bring forward more options.”